Living biodrugs and how tissue source influences mesenchymal stem cell therapeutics for heart failure.

In this editorial we comment on the article by Safwan M . We especially focused on the cardiac function restoration by the use of mesenchymal stem cells (MSCs) therapy for heart failure (HF), which has emerged as a new treatment approach as "Living Biodrugs". HF remains a significant clinical challenge due to the heart's inability to pump blood effectively, despite advancements in medical and device-based therapies.